Shares of NxStage Medical, Inc. (NASDAQ:NXTM) have been given an average recommendation of “Hold” by the ten ratings firms that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and eight have assigned a hold recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $30.00.

Several equities research analysts have weighed in on NXTM shares. Zacks Investment Research cut shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Canaccord Genuity restated a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a research report on Tuesday, October 17th. Northland Securities restated a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a research report on Wednesday, November 8th. Leerink Swann cut shares of NxStage Medical from an “outperform” rating to a “market perform” rating and raised their price objective for the company from $28.00 to $30.00 in a research report on Tuesday, August 22nd. Finally, BTIG Research cut shares of NxStage Medical from a “buy” rating to a “neutral” rating in a research report on Friday, August 11th.

Shares of NxStage Medical (NASDAQ NXTM) traded up $0.52 during trading on Friday, hitting $26.12. 634,406 shares of the company were exchanged, compared to its average volume of 802,138. NxStage Medical has a 1-year low of $20.45 and a 1-year high of $30.80.

In other news, SVP Winifred L. Swan sold 3,500 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $25.73, for a total value of $90,055.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $27.56, for a total transaction of $27,560.00. The disclosure for this sale can be found here. Insiders sold a total of 12,300 shares of company stock worth $331,126 in the last ninety days. Insiders own 4.70% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Prudential Financial Inc. bought a new position in shares of NxStage Medical in the 3rd quarter valued at about $202,000. Amalgamated Bank boosted its stake in shares of NxStage Medical by 7.1% in the 2nd quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock valued at $210,000 after purchasing an additional 553 shares during the last quarter. Athos Capital Ltd bought a new position in shares of NxStage Medical in the 3rd quarter valued at about $557,000. Suntrust Banks Inc. boosted its stake in shares of NxStage Medical by 2.3% in the 2nd quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock valued at $237,000 after purchasing an additional 209 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of NxStage Medical by 217.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,676 shares of the medical device company’s stock valued at $243,000 after purchasing an additional 6,624 shares during the last quarter. 85.68% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “NxStage Medical, Inc. (NXTM) Given Consensus Recommendation of “Hold” by Brokerages” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/12/08/nxstage-medical-inc-nxtm-given-consensus-recommendation-of-hold-by-brokerages-3.html.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Analyst Recommendations for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.